Watch NAGE. Know when insiders buy.
One email the day a filing lands. Free.
NAGE
Niagen Bioscience, Inc.
2.36
−0.04 −1.67%
USD · close Nov 3
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
59
WATCH · shorts 59
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $186.7MP/E 13.1DIV YIELD —FCF YIELD —REV TTM $129.1M +11.0%NET INCOME $16M −9.8%NET CASH $59.1M52W 2.33 – 7.18SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $29.8M | −4.3% | 64.8% | $700K | $963K | −73.3% | 0.01 | $2.8M | — | — | Aug 4 |
| Q1 2026 · Mar 31 | $31.5M | +3.3% | 63.5% | $1.6M | $6.3M | +24.8% | 0.07 | −$1.2M | — | — | May 6 |
| Q4 2025 · Dec 31derived | $33.8M | +16.2% | 64.1% | $4.1M | $4.1M | −42.4% | 0.05 | $679K | — | — | Mar 4 |
| Q3 2025 · Sep 30 | $34M | +32.9% | 64.5% | $4.2M | $4.6M | +143.8% | 0.05 | $3.7M | — | — | Nov 4 |
| Q2 2025 · Jun 30 | $31.1M | +36.8% | 65.0% | $3.2M | $3.6M | — | 0.04 | $1.3M | — | — | Aug 4 |
| Q1 2025 · Mar 31 | $30.5M | +37.6% | 63.4% | $4.8M | $5.1M | — | 0.06 | $7.9M | — | — | May 6 |
| Q4 2024 · Dec 31derived | $29.1M | +37.4% | 62.5% | $7.1M | $7.2M | +6197.4% | 0.09 | $8.6M | — | — | Mar 4 |
| Q3 2024 · Sep 30 | $25.6M | +31.2% | 63.5% | $1.6M | $1.9M | — | 0.02 | $3.5M | — | — | Nov 4 |
| Q2 2024 · Jun 30 | $22.7M | — | 60.2% | −$256K | −$15K | — | 0.00 | −$264K | — | — | Aug 6 |
| Q1 2024 · Mar 31 | $22.2M | — | 60.7% | −$731K | −$492K | — | -0.01 | $295K | — | — | May 7 |
| Q4 2023 · Dec 31derived | $21.2M | — | 61.0% | −$168K | $114K | — | 0.00 | $649K | — | — | Mar 4 |
| Q3 2023 · Sep 30 | $19.5M | — | 61.4% | −$1.1M | −$959K | — | -0.01 | $396K | — | — | Oct 31 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $129.4M | 64.3% | $16.3M | $17.4M | 13.4% | 0.20 | $13.5M | — | — | $251K | — |
| FY2024 · to Dec 31 | $99.6M | 61.8% | $7.7M | $8.6M | 8.6% | 0.11 | $12.1M | — | — | $0 | — |
| FY2023 · to Dec 31 | $83.6M | 60.8% | −$5.6M | −$4.9M | -5.9% | -0.07 | $7.1M | — | — | — | — |
| FY2022 · to Dec 31 | $72M | 59.4% | −$18.6M | −$16.5M | -23.0% | -0.24 | −$15.1M | — | — | — | — |
| FY2021 · to Dec 31 | $67.4M | 61.5% | −$27.1M | −$27.1M | -40.2% | -0.40 | −$24.2M | — | — | — | — |
| FY2020 · to Dec 31 | $59.3M | 59.5% | −$19.9M | −$19.9M | -33.6% | -0.33 | −$10.6M | — | — | — | — |
Every number comes from Niagen Bioscience, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.